Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0471-0119 H · 2 trials · 2 indications
Measured in milligram per kilogram (mg/kg).
| Arm | Type | Description |
|---|---|---|
| NNC0471-0119 H then Insulin Aspart | EXPERIMENTAL | Participants will receive NNC0471-0119 H subcutaneously (s.c.) in period 1 followed by insulin aspart s.c. in period 2. |
| Insulin Aspart then NNC0471-0119 H | ACTIVE_COMPARATOR | Participants will receive insulin aspart s.c. in period 1 followed by s.c. NNC0471-0119 H in period 2. |
| Name | Type | Description |
|---|---|---|
| NNC0471-0119 H | DRUG | NNC0471-0119 H will be administered subcutaneously. |
| Insulin Aspart | DRUG | Insulin aspart will be administered subcutaneously. |
Inclusion Criteria: * Male or female (sex at birth). * Age 18-69 years (both inclusive) at the time of signing the informed consent. * Diagnosed with Type 2 Diabetes (T2D) greater than or equal to (≥) 180 days before screening. * Treated with any injectable insulin, except once-weekly insulin, ≥ 18...
NNC0471-0119 H is an investigational small molecule insulin being developed for the treatment of Type 1 and Type 2 diabetes mellitus. It is administered via an insulin pump and is currently in Phase 1 clinical development.
NNC0471-0119 H is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO.
NNC0471-0119 H is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials have been completed.
NNC0471-0119 H has been studied in two completed Phase 1 trials. NCT06809621 tested the drug in 43 participants with Type 1 diabetes in Germany, and NCT07068295 tested it in 65 participants with Type 2 diabetes in Germany.
NNC0471-0119 H is given by an insulin pump, as indicated in the clinical trial titles for both Type 1 and Type 2 diabetes studies.